Receptor for advanced glycation end products involved in lung ischemia reperfusion injury in cardiopulmonary bypass attenuated by controlled oxygen reperfusion in a canine model

ASAIO Journal

Volumn 59, Issue 3, 2013, Pages 302-308

  Rong, Jian ^a   Ye, Sheng ^a   Liang, Meng Ya ^a   Chen, Guang Xian ^a   Liu, Hai ^a   Zhang, Jin Xin ^a   Wu, Zhong Kai ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

cardiopulmonary bypass; lung ischemia reperfusion injury; oxygen; receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCTS; AORTIC CLAMPING; CARDIOPULMONARY BYPASS; DOWNSTREAM EFFECTS; HIGH-MOBILITY GROUPS; ISCHEMIA-REPERFUSION INJURY; OXYGEN TREATMENT; TUMOR NECROSIS FACTORS;

OXYGEN; PATHOLOGY; TISSUE;

BIOLOGICAL ORGANS;

ADVANCED GLYCATION END PRODUCT RECEPTOR; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CLAMPING; ARTICLE; CARDIOPLEGIA; CARDIOPULMONARY BYPASS; CONTROLLED OXYGEN REPERFUSION; CONTROLLED STUDY; DOWN REGULATION; EXPERIMENTAL DOG; FEMALE; HISTOPATHOLOGY; LUNG INJURY; MALE; NONHUMAN; REPERFUSION; REPERFUSION INJURY; RESPIRATORY TRACT INFLAMMATION;

ANIMALS; BLOTTING, WESTERN; CARDIOPULMONARY BYPASS; DISEASE MODELS, ANIMAL; DOGS; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; INTERLEUKIN-6; LUNG; MALE; OXYGEN; RECEPTORS, IMMUNOLOGIC; REPERFUSION INJURY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84877767403     PISSN: 10582916     EISSN: 1538943X     Source Type: Journal    
DOI: 10.1097/MAT.0b013e318290504e     Document Type: Article

References (33)

1. Gott J P, Cooper WA, Schmidt FE Jr, et al: Modifying risk for extracorporeal circulation: Trial of four antiinfammatory strategies. Ann Thorac Surg 66: 747-753, 1998.
2. Ng CS, Wan S, Yim AP, Arif AA: Pulmonary dysfunction after cardiac surgery. Chest 121: 1269-1277, 2002.
3. Chao YK, Wu YC, Yang KJ, et al: Pulmonary perfusion with L-arginine ameliorates post-cardiopulmonary bypass lung injury in a rabbit model. J Surg Res 167: e77-e83, 2011.
4. Kagawa H, Morita K, Nagahori R, Shinohara G, Kinouchi K, Hashimoto K: Prevention of ischemia/reperfusion-induced pulmonary dysfunction after cardiopulmonary bypass with terminal leukocyte-depleted lung reperfusion. J Thorac Cardiovasc Surg 139: 174-180, 2010.
5. Liangos O, Domhan S, Schwager C, et al: Whole blood transcriptomics in cardiac surgery identifes a gene regulatory network connecting ischemia reperfusion with systemic infammation. PLoS One 5: e13658, 2010.
6. Rong J, Ye S, Wu ZK, et al: Controlled oxygen reperfusion protects the lung against early ischemia-reperfusion injury in cardiopulmonary bypasses by downregulating high mobility group box 1. Exp Lung Res 38: 183-191, 2012.
7. Kokkola R, Andersson A, Mullins G, et al: RAGE is the major receptor for the proinfammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 61: 1-9, 2005.
8. Creagh-Brown BC, Quinlan GJ, Evans TW, Burke-Gaffney A: The RAGE axis in systemic infammation, acute lung injury and myocardial dysfunction: An important therapeutic target? Intensive Care Med 36: 1644-1656, 2010.
9. Sternberg DI, Gowda R, Mehra D, et al: Blockade of receptor for advanced glycation end product attenuates pulmonary reperfusion injury in mice. J Thorac Cardiovasc Surg 136: 1576-1585, 2008.
10. Hori O, Brett J, Slattery T, et al: The receptor for advanced glycation end products (RAGE) is a cellular binding site for ampho-terin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 270: 25752-25761, 1995.
11. Chavakis E, Hain A, Vinci M, et al: High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circ Res 100: 204-212, 2007.
12. Tian J, Avalos AM, Mao SY, et al: Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 8: 487-496, 2007.
13. Committee on Dogs, Institute of Laboratory Animal Resources, Commission on Life Sciences, Council NR: Veterinary Care, Laboratory Animal Management: Dogs. Washington, DC, National Academies Press, 1994, pp. 66-70.
14. King J, Deboisblanc BP, Mason CM, et al: Effect of granulocyte colony-stimulating factor on acute lung injury in the rat. Am J Respir Crit Care Med 151(2 pt 1): 302-309, 1995.
15. Volz HC, Kaya Z, Katus HA, Andrassy M: The role of HMGB1/RAGE in infammatory cardiomyopathy. Semin Thromb Hemost 36: 185-194, 2010.
16. Neeper M, Schmidt AM, Brett J, et al: Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267: 14998-15004, 1992.
17. Uchida T, Shirasawa M, Ware LB, et al: Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. Am J Respir Crit Care Med 173: 1008-1015, 2006.
18. Zhang H, Tasaka S, Shiraishi Y, et al: Role of soluble receptor for advanced glycation end products on endotoxin-induced lung injury. Am J Respir Crit Care Med 178: 356-362, 2008.
19. Fink MP: Bench-to-bedside review: High-mobility group box 1 and critical illness. Crit Care 11: 229, 2007.
20. Buckley ST, Ehrhardt C: The receptor for advanced glycation end products (RAGE) and the lung. J Biomed Biotechnol 2010: 917108, 2010.
21. Su X, Looney MR, Gupta N, Matthay MA: Receptor for advanced glycation end-products (RAGE) is an indicator of direct lung injury in models of experimental lung injury. Am J Physiol Lung Cell Mol Physiol 297: L1-L5, 2009.
22. Reynolds PR, Schmitt RE, Kasteler SD, et al: Receptors for advanced glycation end-products targeting protect against hyperoxia-induced lung injury in mice. Am J Respir Cell Mol Biol 42: 545-551, 2010.
23. Shang L, Ananthakrishnan R, Li Q, et al: RAGE modulates hypoxia/reoxygenation injury in adult murine cardiomyocytes via JNK and GSK-3beta signaling pathways. PLoS One 5: e10092, 2010.
24. Edmark L, Auner U, Enlund M, Ostberg E, Hedenstierna G: Oxygen concentration and characteristics of progressive atelec-tasis formation during anaesthesia. Acta Anaesthesiol Scand 55: 75-81, 2011.
25. Ellman PI, Alvis JS, Tache-Leon C, et al: Hyperoxic ventilation exacerbates lung reperfusion injury. J Thorac Cardiovasc Surg 130: 1440, 2005.
26. Kilgannon JH, Jones AE, Shapiro NI, et al; Emergency Medicine Shock Research Network (EMShockNet) Investigators: Association between arterial hyperoxia following resuscitation from cardiac arrest and in-hospital mortality. JAMA 303: 2165-2171, 2010.
27. Tamion F, Richard V, Bonmarchand G, et al: Reduced synthesis of infammatory cytokines by a free radical scavenger after hemor-rhagic shock in rats. Crit Care Med 28: 2522-2527, 2000.
28. Caputo M, Mokhtari A, Rogers CA, et al: The effects of normoxic versus hyperoxic cardiopulmonary bypass on oxidative stress and infammatory response in cyanotic pediatric patients undergoing open cardiac surgery: A randomized controlled trial. J Thorac Cardiovasc Surg 138: 206-214, 2009.
29. Douzinas EE, Betrosian A, Giamarellos-Bourboulis EJ, et al: Hypoxemic resuscitation from hemorrhagic shock prevents lung injury and attenuates oxidative response and IL-8 overex-pression. Free Radic Biol Med 50: 245-253, 2011.
30. Ghorbel MT, Mokhtari A, Sheikh M, Angelini GD, Caputo M: Controlled reoxygenation cardiopulmonary bypass is associated with reduced transcriptomic changes in cyanotic tetralogy of Fallot patients undergoing surgery. Physiol Genomics 44: 1098-1106, 2012.
31. Andrassy M, Volz HC, Igwe JC, et al: High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 117: 3216-3226, 2008.
32. Cai B, Chen F, Lin X, et al: Anti-infammatory adjuvant in resuscitation fuids improves survival in hemorrhage. Crit Care Med 37: 860-868, 2009.
33. van Zoelen MA, Schouten M, de Vos AF, et al: The receptor for advanced glycation end products impairs host defense in pneu-mococcal pneumonia. J Immunol 182: 4349-4356, 2009.